C2i Genomics is a leading brand in the field of life sciences and deep tech. Our mission is to provide researchers, physicians, and patients with ultra-sensitive whole-genome cancer detection. With our SaaS solution and cloud-based platform, we enable global-scale cancer tumor burden monitoring by leveraging existing genome sequencers worldwide.

Using cutting-edge scientific breakthroughs, advanced signal processing, and AI technology, we empower precision personalized medicine, reduce cancer treatment costs, and accelerate drug development. Founded in 2019, C2i Genomics is backed by top-tier VCs and has headquarters in the US, with a CLIA lab in Cambridge, MA, and an R&D center in Israel. We have assembled a team of experts in oncology, signal processing, bioinformatics, and machine learning.

Located in New York, Haifa, and Watertown, our offices are strategically situated in vibrant life science hubs. We have partnerships with selected investors and offer exciting career opportunities in empowering cancer detection. At C2i Genomics, we are dedicated to making a difference in the fight against cancer.

Contact us to learn more about our groundbreaking solutions. (Note: C2i Genomics' diagnostic services have not yet received clearance or approval from the U. S.

FDA. )